Nephros Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Nephros Inc. has submitted its annual 10-K filing for the fiscal year 2023, detailing its financial performance and business operations.</b>

AI Summary

NEPHROS INC (NEPH) filed a Annual Report (10-K) with the SEC on March 15, 2024. Nephros Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is 380 Lackawanna Place, South Orange, NJ 07079. Nephros Inc. is classified under SIC code 3841 for Surgical & Medical Instruments & Apparatus. The report was filed on March 15, 2024.

Why It Matters

For investors and stakeholders tracking NEPHROS INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Nephros Inc.'s financial health, operational results, and strategic positioning for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and disclosures within the 10-K allow stakeholders to understand the company's revenue streams, expenses, assets, liabilities, and overall financial stability, aiding in investment decisions.

Risk Assessment

Risk Level: low — NEPHROS INC shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant negative financial news or events, indicating a routine disclosure.

Analyst Insight

Investors should review the detailed financial statements and management's discussion and analysis within the 10-K to understand Nephros Inc.'s performance and outlook for 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-15 — Filing Date (Filed as of date)
• 3841 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• NEPHROS INC (company) — Filer name
• 380 Lackawanna Place (location) — Business address
• South Orange (location) — Business address city
• NJ (location) — Business address state
• 07079 (location) — Business address zip
• 201.343.5202 (phone) — Business phone
• 1934 Act (regulation) — SEC Act
• 001-32288 (identifier) — SEC file number

FAQ

Industry Context

Nephros Inc. operates in the Surgical & Medical Instruments & Apparatus industry, focusing on products related to dialysis and kidney disease treatment.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information about their business, financial condition, and operations.

What Investors Should Do

1. Review the full 10-K document for detailed financial statements and disclosures.
2. Analyze the company's performance metrics and compare them to previous periods.
3. Assess any new risk factors or management commentary provided in the report.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-15: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the 2023 annual report (10-K) filing, providing year-end financial and operational data.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share NEPH The Nasdaq Stock Mar
• $1.5 million — an outstanding balance of approximately $1.5 million. Accordingly, SRP assigned to us all of

Filing Documents

• form10-k.htm (10-K) — 1321KB
• ex10-31.htm (EX-10.31) — 20KB
• ex10-32.htm (EX-10.32) — 51KB
• ex10-34.htm (EX-10.34) — 183KB
• ex21-1.htm (EX-21.1) — 5KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• ex97-1.htm (EX-97.1) — 49KB
• ex10-31_001.jpg (GRAPHIC) — 11KB
• ex10-31_002.jpg (GRAPHIC) — 4KB
• ex10-31_003.jpg (GRAPHIC) — 4KB
• ex10-31_004.jpg (GRAPHIC) — 4KB
• 0001493152-24-010107.txt (&nbsp;) — 7541KB
• neph-20231231.xsd (EX-101.SCH) — 51KB
• neph-20231231_cal.xml (EX-101.CAL) — 85KB
• neph-20231231_def.xml (EX-101.DEF) — 220KB
• neph-20231231_lab.xml (EX-101.LAB) — 480KB
• neph-20231231_pre.xml (EX-101.PRE) — 369KB
• form10-k_htm.xml (XML) — 1064KB

Risk Factors

Item 1A. Risk Factors 14

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 21

Properties

Item 2. Properties 23

Legal Proceedings

Item 3. Legal Proceedings 23

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 23 PART II 24

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 24

Selected Financial Data

Item 6. Selected Financial Data 24

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 28

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 28

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 53

Controls and Procedures

Item 9A. Controls and Procedures 53

Other Information

Item 9B. Other Information 53 PART III 54

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 54

Executive Compensation

Item 11. Executive Compensation 54

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 54

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 54

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 54 PART IV 55

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules 55

Form 10K Summary

Item 16. Form 10K Summary 58

SIGNATURES

SIGNATURES 59 2 FORWARD LOOKING STATEMENTS The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain statements in this Annual Report on Form 10-K constitute "forward-looking statements." Such statements include statements regarding our ability to increase our revenue, limit our expenses and other expected operating results, including our ability and the timing of our business generating positive cash flows from operations, the adequacy of our existing capital resources to fund our operations, our belief that we will maintain good relationships with our suppliers, distributors and customers, and other statements that are not historical facts, including statements that may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include, but are not limited to, the risks that: we face significant challenges in obtaining market acceptance of our products, which, if not obtained, could adversely affect our potential sales and revenues; product-related deaths or serious injuries or product malfunctions could trigger recalls, class action lawsuits and other events that could cause us to incur expenses and may also limit our ability to generate revenues from such products; we face potential liability associated with the production, marketing and sale of our products, and the expense of defending against claims of product liability could materially deplete our assets and generate negative publicity, which could impair our reputatio

View Full Filing

View this 10-K filing on SEC EDGAR